1. DOP75 Loss-of-response and immunogenicity following immunomodulator withdrawal from anti-tumour necrosis factor alpha combination therapy: Results from a large retrospective cohort study. (27th May 2021) Authors: Mahmoud, R; Schultheiss, J; Louwers, J; van der Kaaij, M; van Hellemondt, B; Mahmmod, N; van Boeckel, P; Jharap, B; Fidder, H; Oldenburg, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Issue 4 (2nd October 2008) Authors: Schnitzler, F; Fidder, H; Ferrante, M; Noman, M; Arijs, I; Van Assche, G; Hoffman, I; Van Steen, K; Vermeire, S; Rutgeerts, P Journal: Gut Issue: Volume 58:Issue 4(2009) Page Start: 492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Issue 4 (2nd October 2008) Authors: Fidder, H; Schnitzler, F; Ferrante, M; Noman, M; Katsanos, K; Segaert, S; Henckaerts, L; Van Assche, G; Vermeire, S; Rutgeerts, P Journal: Gut Issue: Volume 58:Issue 4(2009) Page Start: 501 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P299 Loss-of-response to anti-tumour necrosis factor-α critically depends on treatment duration in patients with Inflammatory Bowel Disease. (27th May 2021) Authors: Schultheiss, J; Mahmoud, R; Louwers, J; van der Kaaij, M; van Hellemondt, B; van Boeckel, P; Mahmmod, N; Jharap, B; Fidder, H; Oldenburg, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P312 Erythrocyte methotrexate polyglutamate concentrations in patients with Crohn's Disease: towards a new therapeutic drug monitoring tool. (27th May 2021) Authors: Van de Meeberg, M; Lin, M; Seinen, M; Fidder, H; Oldenburg, B; Bouma, G; de Jonge, R; Bulatović Ćalasan, M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P384 A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn's Disease: first results of a prospective cohort. (30th January 2023) Authors: Van De Meeberg, M; Fidder, H; Sundaresan, J; Struys, E; Oldenburg, B; Mares, W; Mahmmod, N; van Asseldonk, D; Lutgens, M; Kuyvenhoven, J; Rietdijk, S; Nissen, L; Koehestanie, P; de Jonge, R; Bulatović Ćalasan, M; Bouma, G Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i518 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P397 Autologous stem cell transplantation in refractory Crohn's disease: evaluation of a modified mobilisation regimen and analyses of the cost-effectiveness. (25th January 2019) Authors: Mahmmod, N; Mahmmod, S; Severs, M; Koene, H; van Wijk, F; Oldenburg, B; Fidder, H Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P414 Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease. (27th May 2021) Authors: Mahmoud, R; Schultheiss, J; Louwers, J; van der Kaaij, M; van Hellemondt, B; Mahmmod, N; van Boeckel, P; Jharap, B; Fidder, H; Oldenburg, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P448 Cannabis and cannabinoids for the treatment of inflammatory bowel disease: a systematic review and meta-analysis. (25th January 2019) Authors: Doeve, B; van Schaik, F; van de Meeberg, M; Fidder, H Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P687 Female sex is associated with discontinuation of subcutaneous anti-TNF therapy for side effects in inflammatory bowel disease. (16th January 2018) Authors: Schultheiss, J; Lamers, E; Brand, E; Fidder, H Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗